Treace Medical Concepts Inc. (TMCI)
NASDAQ: TMCIHealthcareMedical DevicesUSD
At close: Oct 7, 4:00 PM ET · Delayed 15 min
TMCI stock chart
Technical analysisKey statistics
All statistics- Market cap
- $252.98M
- EPS (TTM)
- -$0.92
- Dividend yield
- None
- 52-week range
- 1.17 – 7.08
- Day range
- 3.82 – 4.12
- Volume / Avg
- 250.34K / 333.87K
- Beta
- —
- Shares outstanding
- 65.03M
- Next earnings
- Nov 5, 2026
52-week range
TMCI stock today
Treace Medical Concepts (TMCI) closed at $3.89 on Oct 7, down 2.75% (-$0.11), versus the S&P 500's 0.22% decline. Shares are 45.1% below their 52-week high of $7.08, set on Oct 22, 2025 and 232.5% above the 52-week low of $1.17, in the middle of the past year's range. TMCI is up 58.8% year to date, outperforming the S&P 500 (+14.0%). Over the past 12 months, the stock has lost 35.2%.
Treace Medical Concepts has posted a net loss over the last twelve months (EPS of -$0.92), so its P/E ratio is not meaningful. Treace Medical Concepts's next earnings report is expected on Nov 5, 2026.
Summary generated from market data by MetaCap's automated system. Methodology
About Treace Medical Concepts
Company profileTreace Medical Concepts, Inc., a medical technology company, designs, manufactures, and markets medical devices in the United States. The company offers Lapiplasty System, enables surgeons to correct all three dimensions of the bunion deformity, stabilize the first TMT joint, and allow return to weight-bearing in a walking boot; minimally invasive products for four bunion classes; Nanoplasty 3D Minimally Invasive Bunion Correction System delivers a reproducible 3D correction of the bunion deformity through a cosmetically appealing; and Percuplasty Percutaneous 3D Bunion Correction System that provides 3D correction of the bunion deformity through percutaneous incisions. It also provides Adductoplasty System, a system designed for the correction of metatarsus adductus deformities and osteoarthritis of the midfoot; SpeedMTP Rapid Compression Implant; SpeedPlate Implant Fixation Platform to address the fusion of larger bones of the midfoot and rearfoot; SpeedPlate Micro-Quad implant, an implant designed for stability and fit in small incision surgical approaches; and SpeedAkin Anatomic Compression Implant.
- Sector
- Healthcare
- Industry
- Medical Devices
- CEO
- Mr. John T. Treace
- Headquarters
- Ponte Vedra, FL
- Employees
- 450
- IPO year
- 2021
- Website
- treace.com
Analyst forecast
ForecastConsensus (5 analysts)
none
Avg. price target
$5.50+41.39%
- Strong buy 0
- Buy 1
- Hold 3
- Sell 0
- Strong sell 1
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Next report
- Nov 5, 2026
- EPS estimate
- $-0.25
Treace Medical Concepts peers
Healthcare sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| TLSITriSalus Life Sciences Inc. | 4.25 | -0.47% | $261.69M | vs TMCI |
| INFUInfuSystems Holdings Inc. | 13.33 | +0.45% | $265.50M | vs TMCI |
| LABStandard BioTools Inc. | 0.6787 | -6.00% | $266.44M | vs TMCI |
| ELMDElectromed Inc. | 28.20 | -0.25% | $233.70M | vs TMCI |
| QSIQuantum-Si Incorporated Class A | 1.28 | +4.92% | $280.17M | vs TMCI |
| CATXPerspective Therapeutics Inc. | 2.46 | +4.24% | $280.81M | vs TMCI |
| MOBIMobia Medical Inc. | 8.51 | -3.30% | $283.31M | vs TMCI |
| PROFProfound Medical Corp. | 5.68 | -6.58% | $207.55M | vs TMCI |
Indexes, lists and sector
Appears in lists
Treace Medical Concepts stock FAQ
What is Treace Medical Concepts's stock price today?
TMCI last traded at $3.89 as of Oct 7, 4:00 PM EDT, down 2.75% on the day. Prices are delayed at least 15 minutes.
When is Treace Medical Concepts's next earnings date?
Treace Medical Concepts is expected to report earnings on Thursday, November 5, 2026. Analysts expect EPS of $-0.25.
Who is Treace Medical Concepts's CEO?
Mr. John T. Treace is the chief executive officer of Treace Medical Concepts Inc., which has about 450 employees.
What is the TMCI 52-week high?
The 52-week high for TMCI is $7.08 and the 52-week low is $1.17. The stock is currently 45.1% below its high.